After half a century with no new drug approvals and no clear regulatory pathway, the lupus field is finally seeing some progress. And the trial design that helped Human Genome Sciences Inc.'s lupus drug Benlysta (belimumab) achieve Phase III success and win an FDA advisory committee's support last week is already being emulated by up-and-comers in the field, some of which are applying their own spin. Read More
